WO2007084391A3 - Thiazole compounds as protein kinase b ( pkb) inhibitors - Google Patents
Thiazole compounds as protein kinase b ( pkb) inhibitors Download PDFInfo
- Publication number
- WO2007084391A3 WO2007084391A3 PCT/US2007/000871 US2007000871W WO2007084391A3 WO 2007084391 A3 WO2007084391 A3 WO 2007084391A3 US 2007000871 W US2007000871 W US 2007000871W WO 2007084391 A3 WO2007084391 A3 WO 2007084391A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiazole compounds
- pkb
- protein kinase
- inhibitors
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0706621-0A BRPI0706621A2 (en) | 2006-01-18 | 2007-01-11 | compound, pharmaceutical composition, methods for treating a kinase-mediated disorder in a mammal and for treating a proliferation-related disorder in a mammal, and, use of the compound |
JP2008551297A JP5199885B2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase B (PKB) inhibitors |
EA200801716A EA200801716A1 (en) | 2006-01-18 | 2007-01-11 | THIAZOLE COMPOUNDS AND THEIR APPLICATION |
CA2636077A CA2636077C (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b (pkb) inhibitors |
ES07718125T ES2389062T3 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase B inhibitors (PKB) |
EP07718125A EP1981884B1 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b (pkb) inhibitors |
AU2007207743A AU2007207743B2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase B (PKB) inhibitors |
IL192751A IL192751A0 (en) | 2006-01-18 | 2008-07-10 | Thiazole compounds as protein kinase b (pkb) inhibitors |
NO20083572A NO20083572L (en) | 2006-01-18 | 2008-08-18 | Thiazole compounds as protein kinase-B (PKB) inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75954606P | 2006-01-18 | 2006-01-18 | |
US60/759,546 | 2006-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007084391A2 WO2007084391A2 (en) | 2007-07-26 |
WO2007084391A3 true WO2007084391A3 (en) | 2008-03-20 |
Family
ID=38180602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/000871 WO2007084391A2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b ( pkb) inhibitors |
Country Status (21)
Country | Link |
---|---|
US (2) | US7514566B2 (en) |
EP (1) | EP1981884B1 (en) |
JP (1) | JP5199885B2 (en) |
KR (1) | KR20080091369A (en) |
CN (1) | CN101421265A (en) |
AR (1) | AR059064A1 (en) |
AU (1) | AU2007207743B2 (en) |
BR (1) | BRPI0706621A2 (en) |
CA (1) | CA2636077C (en) |
CR (1) | CR10211A (en) |
EA (1) | EA200801716A1 (en) |
ES (1) | ES2389062T3 (en) |
IL (1) | IL192751A0 (en) |
MY (1) | MY149143A (en) |
NO (1) | NO20083572L (en) |
PE (1) | PE20071114A1 (en) |
TW (1) | TW200738657A (en) |
UA (1) | UA91895C2 (en) |
UY (1) | UY30098A1 (en) |
WO (1) | WO2007084391A2 (en) |
ZA (1) | ZA200806386B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA012181B1 (en) | 2004-10-18 | 2009-08-28 | Амген, Инк. | Thiadiazole compounds and use thereof |
EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
JP2010518159A (en) * | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | Function-selective α2C adrenergic receptor agonist |
US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
WO2009158372A1 (en) * | 2008-06-26 | 2009-12-30 | Smithkline Beecham Corporation | Inhibitors of akt activity |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
CN102186833A (en) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | MIF modulators |
LT2356109T (en) * | 2008-10-10 | 2017-03-27 | Vm Discovery, Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
US8232273B2 (en) * | 2008-12-19 | 2012-07-31 | Genentech, Inc. | Heterocyclic compounds and methods of use |
EP2387570A1 (en) * | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
EP2440556A1 (en) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
DK2445502T4 (en) | 2009-06-25 | 2022-11-28 | Alkermes Pharma Ireland Ltd | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS |
ES2532026T3 (en) * | 2009-10-08 | 2015-03-23 | Glaxosmithkline Llc | Combination |
EA023018B1 (en) * | 2009-10-08 | 2016-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Combination for treating cancer and/or pre-cancerous syndromes |
BR112012008519A2 (en) * | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combination |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
EA027123B1 (en) | 2009-11-05 | 2017-06-30 | Ризен Фармасьютикалз С.А. | Pi3k kinase inhibitors |
WO2011115071A1 (en) * | 2010-03-15 | 2011-09-22 | 国立大学法人広島大学 | Thienopyridine derivative, method for producing same and organic semiconductor device using same |
JP5578705B2 (en) * | 2010-03-29 | 2014-08-27 | 公益財団法人相模中央化学研究所 | (Aryl) difluoroacetic acid ester derivative and method for producing the same |
CN102933571A (en) * | 2010-04-16 | 2013-02-13 | Abbvie公司 | Phthalazin-(2h)-one inhibitors of kinases |
EP2579872A4 (en) * | 2010-04-23 | 2013-11-13 | Merck Sharp & Dohme | Inhibitors of akt activity |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JO2998B1 (en) | 2010-06-04 | 2016-09-05 | Amgen Inc | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
AU2012250576B2 (en) | 2011-05-04 | 2017-04-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinases |
AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
CN103304468A (en) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | One-pot series synthetic method of oxoindole |
EP2832731A4 (en) * | 2012-03-27 | 2015-08-19 | Shionogi & Co | Aromatic heterocyclic five-membered ring derivative having trpv4 inhibitory activity |
WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
EP2870157B1 (en) | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selective pi3k delta inhibitors |
US20160002185A1 (en) | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
BR112015022431A2 (en) * | 2013-03-13 | 2017-05-09 | Boston Biomedical Inc | 3- (aryl or heteroaryl) methyleneindolin-2-one derivatives as cancer stem cell signaling pathway kinase inhibitors for cancer treatment |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (en) | 2013-06-10 | 2017-06-16 | Amgen Inc | Processes of Making and Crystalline Forms of a MDM2 Inhibitor |
EP3068393B9 (en) | 2013-11-11 | 2022-07-20 | Amgen Inc. | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
KR20170122799A (en) * | 2015-03-02 | 2017-11-06 | 리겔 파마슈티칼스, 인크. | TGF-beta Inhibitor |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
EP3426652B1 (en) * | 2016-03-10 | 2021-12-01 | Astrazeneca AB | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
DK3691620T3 (en) | 2017-10-05 | 2022-10-03 | Fulcrum Therapeutics Inc | P38 KINASE INHIBITOR REDUCES DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD |
EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
JP7266043B2 (en) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C inhibitors and methods of using them |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
AU2020280024A1 (en) | 2019-05-21 | 2021-12-09 | Amgen Inc. | Solid state forms |
AU2020325115A1 (en) * | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021126816A1 (en) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Dosing regimen of a kras g12c inhibitor |
CN111603466B (en) * | 2020-06-29 | 2022-07-22 | 江南大学 | Application of ethanone compound in preparation of tumor treatment drug |
CN114014787B (en) * | 2022-01-10 | 2022-03-22 | 苏州开元民生科技股份有限公司 | Asymmetric synthesis method for preparing (2S,3R) -p-methylsulfonylphenylserine ethyl ester |
CN116813608A (en) * | 2023-06-08 | 2023-09-29 | 英矽智能科技(上海)有限公司 | Thiazole compound and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297365A (en) * | 1978-08-04 | 1981-10-27 | Ciba-Geigy Corporation | Benzimidazoles and pharmaceutical preparations containing such compounds |
US20010044545A1 (en) * | 2000-04-03 | 2001-11-22 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US20030078252A1 (en) * | 2001-05-11 | 2003-04-24 | Pfizer Inc. | Thiazole derivatives |
US20040122016A1 (en) * | 2002-10-30 | 2004-06-24 | Jingrong Cao | Compositions useful as inhibitors of rock and other protein kinases |
WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
WO2006044860A2 (en) * | 2004-10-18 | 2006-04-27 | Amgen, Inc. | Thiadiazole compounds and methods of use |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591600A (en) | 1969-07-07 | 1971-07-06 | Stauffer Chemical Co | 2-aminothiazole phosphates and phosphonates |
GB1435139A (en) | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
JPS5239827B2 (en) | 1973-11-08 | 1977-10-07 | ||
US4086239A (en) | 1977-07-01 | 1978-04-25 | Stauffer Chemical Company | Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods |
DK150068C (en) | 1978-06-02 | 1987-06-29 | Pfizer | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINOTHIAZOLES |
US4451471A (en) | 1981-03-18 | 1984-05-29 | Ciba-Geigy Corporation | Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same |
FR2511375A1 (en) | 1981-08-17 | 1983-02-18 | Rhone Poulenc Sante | NEW DERIVATIVES OF CEPHALOSPORINE, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM |
DE3630732A1 (en) | 1986-09-10 | 1988-03-17 | Bayer Ag | 2-CYANO-2-ALKOXIMINO ACETAMIDE |
US5232921A (en) * | 1987-03-12 | 1993-08-03 | Sanofi | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions |
JPH0753666B2 (en) | 1987-09-14 | 1995-06-07 | 久光製薬株式会社 | Anti-inflammatory agent consisting of substituted diphenylthiazole derivative |
FR2636628B1 (en) | 1988-08-25 | 1990-12-28 | Sanofi Sa | THIADIAZOLE-1,3,4 DERIVATIVES, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US5302608A (en) | 1988-11-18 | 1994-04-12 | Takeda Chemical Industries, Ltd. | Age formation inhibitors |
US5145860A (en) | 1989-01-05 | 1992-09-08 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds and pharmaceutical composition comprising the same |
US5550138A (en) | 1992-03-25 | 1996-08-27 | Takeda Chemical Industries, Ltd. | Condensed thiadiazole derivative, method of its production, and use thereof |
US5856347A (en) | 1994-11-29 | 1999-01-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
FR2735777B1 (en) | 1995-06-21 | 1997-09-12 | Sanofi Sa | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6407124B1 (en) | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
EP1087951B9 (en) | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
EP1150565A1 (en) | 1999-02-08 | 2001-11-07 | LION bioscience AG | Thiazole derivatives and combinatorial libraries thereof |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
AU6471300A (en) | 1999-08-06 | 2001-03-05 | Takeda Chemical Industries Ltd. | P38map kinase inhibitors |
JP2001114690A (en) * | 1999-08-06 | 2001-04-24 | Takeda Chem Ind Ltd | p38MAP KINASE INHIBITOR |
AU2001244618A1 (en) | 2000-03-30 | 2001-10-15 | Takeda Chemical Industries Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US7074934B2 (en) | 2000-06-13 | 2006-07-11 | Tularik Limited | Serine protease inhibitors |
GT200100147A (en) | 2000-07-31 | 2002-06-25 | IMIDAZOL DERIVATIVES | |
JP4689801B2 (en) | 2000-08-09 | 2011-05-25 | ケミプロ化成株式会社 | Method for producing aminothiazole derivative |
JP2002053566A (en) | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | Thiazole compound and pharmaceutical use thereof |
GB0114185D0 (en) | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
AR032653A1 (en) | 2001-02-09 | 2003-11-19 | Telik Inc | HYPERCYCLIC INHIBITORS OF THE GLICINE TRANSPORTER 2 PHARMACEUTICAL COMPOSITIONS, USE AND METHODS. |
US20050080113A1 (en) | 2001-06-11 | 2005-04-14 | Shigenori Ohkawa | Medicinal compositions |
AR039059A1 (en) | 2001-08-06 | 2005-02-09 | Sanofi Aventis | COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS |
JP4495963B2 (en) * | 2001-09-28 | 2010-07-07 | サイクラセル リミテッド | N- (4- (4-methylthiazol-5-yl) pyrimidin-2-yl) -N-phenylamines as antiproliferative compounds |
GB0123589D0 (en) | 2001-10-01 | 2001-11-21 | Syngenta Participations Ag | Organic compounds |
WO2003039451A2 (en) | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
CA2472763A1 (en) | 2002-02-13 | 2003-08-21 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
AU2003210305B2 (en) | 2002-02-28 | 2006-07-06 | F. Hoffmann-La Roche Ag | Thiazole derivatives as NPY receptor antagonists |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
EP1507534A4 (en) | 2002-05-10 | 2006-11-08 | Cytokinetics Inc | Compounds, compositions and methods |
FR2842523A1 (en) | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
EP1551815A1 (en) | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
CL2003002353A1 (en) | 2002-11-15 | 2005-02-04 | Vertex Pharma | COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
FR2850380B1 (en) | 2003-01-23 | 2006-07-07 | Sanofi Synthelabo | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
JP2006182648A (en) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | 7-membered heterocyclic derivative |
AR044519A1 (en) | 2003-05-02 | 2005-09-14 | Novartis Ag | DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA |
CA2536253A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
KR20060088537A (en) | 2003-09-06 | 2006-08-04 | 버텍스 파마슈티칼스 인코포레이티드 | Modulators of atp-binding cassette transporters |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
SI1709019T1 (en) | 2004-01-12 | 2007-10-31 | Serono Lab | Thiazole derivatives and use thereof |
WO2005073202A1 (en) | 2004-01-16 | 2005-08-11 | Sanofi-Aventis | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors |
EP1709041A1 (en) | 2004-01-16 | 2006-10-11 | Sanofi-Aventis | Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics |
WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
JP4054845B2 (en) | 2004-03-23 | 2008-03-05 | ファイザー・プロダクツ・インク | Imidazole compounds for the treatment of neurodegenerative disorders |
CA2561977A1 (en) | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
EP1740609A2 (en) * | 2004-04-27 | 2007-01-10 | Research Development Foundation | Antagonism of tgf-beta superfamily receptor signaling |
AU2005245962A1 (en) | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
GB0411791D0 (en) | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
CA2575466A1 (en) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of atp-utilizing enzymes |
SE0402735D0 (en) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
EP1854793A4 (en) | 2005-02-28 | 2011-01-26 | Japan Tobacco Inc | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY |
KR101386282B1 (en) | 2005-06-17 | 2014-04-17 | 아포지 바이오테크놀로지 코포레이션 | Sphingosine kinase inhibitors |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
DE102005048072A1 (en) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazoles as fungicides |
JP5064237B2 (en) | 2005-12-09 | 2012-10-31 | Meiji Seikaファルマ株式会社 | Lincomycin derivatives and antibacterial agents containing the same as active ingredients |
CN101331125A (en) | 2005-12-12 | 2008-12-24 | 健亚生物科技公司 | N-(5-membered aromatic ring)-amido anti-viral compounds |
AU2007207706A1 (en) | 2006-01-18 | 2007-07-26 | Merck Sharp & Dohme Corp. | Cannibinoid receptor modulators |
JP2009523751A (en) | 2006-01-18 | 2009-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | Cis-4,5-biaryl-2-heterocyclic-imidazoline as an MDM2 inhibitor |
EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
-
2007
- 2007-01-11 EP EP07718125A patent/EP1981884B1/en active Active
- 2007-01-11 CN CNA2007800097081A patent/CN101421265A/en active Pending
- 2007-01-11 AU AU2007207743A patent/AU2007207743B2/en not_active Ceased
- 2007-01-11 US US11/652,728 patent/US7514566B2/en active Active
- 2007-01-11 BR BRPI0706621-0A patent/BRPI0706621A2/en not_active IP Right Cessation
- 2007-01-11 ES ES07718125T patent/ES2389062T3/en active Active
- 2007-01-11 JP JP2008551297A patent/JP5199885B2/en not_active Expired - Fee Related
- 2007-01-11 EA EA200801716A patent/EA200801716A1/en unknown
- 2007-01-11 MY MYPI20082598A patent/MY149143A/en unknown
- 2007-01-11 KR KR1020087019941A patent/KR20080091369A/en not_active Application Discontinuation
- 2007-01-11 WO PCT/US2007/000871 patent/WO2007084391A2/en active Application Filing
- 2007-01-11 CA CA2636077A patent/CA2636077C/en not_active Expired - Fee Related
- 2007-01-17 TW TW096101796A patent/TW200738657A/en unknown
- 2007-01-18 AR ARP070100212A patent/AR059064A1/en unknown
- 2007-01-18 UY UY30098A patent/UY30098A1/en not_active Application Discontinuation
- 2007-01-18 PE PE2007000057A patent/PE20071114A1/en not_active Application Discontinuation
- 2007-11-01 UA UAA200810455A patent/UA91895C2/en unknown
-
2008
- 2008-07-10 IL IL192751A patent/IL192751A0/en unknown
- 2008-07-23 ZA ZA200806386A patent/ZA200806386B/en unknown
- 2008-08-18 NO NO20083572A patent/NO20083572L/en not_active Application Discontinuation
- 2008-08-18 CR CR10211A patent/CR10211A/en not_active Application Discontinuation
-
2009
- 2009-02-11 US US12/378,195 patent/US8084479B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297365A (en) * | 1978-08-04 | 1981-10-27 | Ciba-Geigy Corporation | Benzimidazoles and pharmaceutical preparations containing such compounds |
US20010044545A1 (en) * | 2000-04-03 | 2001-11-22 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US20030078252A1 (en) * | 2001-05-11 | 2003-04-24 | Pfizer Inc. | Thiazole derivatives |
US20040122016A1 (en) * | 2002-10-30 | 2004-06-24 | Jingrong Cao | Compositions useful as inhibitors of rock and other protein kinases |
WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
WO2006044860A2 (en) * | 2004-10-18 | 2006-04-27 | Amgen, Inc. | Thiadiazole compounds and methods of use |
Non-Patent Citations (2)
Title |
---|
KODOMARI M ET AL: "One-pot synthesis of 2-aminothiazoles using supported reagents", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 9, 25 February 2002 (2002-02-25), pages 1717 - 1720, XP004340154, ISSN: 0040-4039 * |
VIJAI N. PATHAK AND RAJ PAL SINGH: "Synthesis and biological properties of some new 2-(N-arylamino)-4-(fluoroaryl)thiazoles", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 56, no. 10, 1979, pages 1010 - 1012, XP009094043 * |
Also Published As
Publication number | Publication date |
---|---|
UA91895C2 (en) | 2010-09-10 |
CN101421265A (en) | 2009-04-29 |
NO20083572L (en) | 2008-10-17 |
AU2007207743B2 (en) | 2010-07-08 |
PE20071114A1 (en) | 2008-01-10 |
TW200738657A (en) | 2007-10-16 |
IL192751A0 (en) | 2009-02-11 |
JP5199885B2 (en) | 2013-05-15 |
ES2389062T3 (en) | 2012-10-22 |
AR059064A1 (en) | 2008-03-12 |
UY30098A1 (en) | 2007-10-31 |
ZA200806386B (en) | 2009-11-25 |
MY149143A (en) | 2013-07-15 |
EP1981884B1 (en) | 2012-06-13 |
US20070173506A1 (en) | 2007-07-26 |
CR10211A (en) | 2008-10-03 |
KR20080091369A (en) | 2008-10-10 |
EP1981884A2 (en) | 2008-10-22 |
CA2636077A1 (en) | 2007-07-26 |
US8084479B2 (en) | 2011-12-27 |
CA2636077C (en) | 2012-01-03 |
US20090270445A1 (en) | 2009-10-29 |
WO2007084391A2 (en) | 2007-07-26 |
EA200801716A1 (en) | 2009-04-28 |
AU2007207743A1 (en) | 2007-07-26 |
US7514566B2 (en) | 2009-04-07 |
BRPI0706621A2 (en) | 2011-04-05 |
JP2009525960A (en) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007084391A3 (en) | Thiazole compounds as protein kinase b ( pkb) inhibitors | |
WO2009011880A3 (en) | Heterocyclic modulators of pkb | |
WO2009011871A3 (en) | Thiadiazole modulators of pkb | |
WO2006044860A3 (en) | Thiadiazole compounds and methods of use | |
WO2009011850A3 (en) | Novel therapeutic compounds | |
WO2008073933A3 (en) | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | |
WO2006093547A3 (en) | Novel lipoxygenase inhibitors | |
MY155418A (en) | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | |
WO2008089307A3 (en) | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer | |
WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
WO2005090333A8 (en) | 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | |
WO2008085794A3 (en) | Methods and compositions related to clot binding compounds | |
NO20084652L (en) | Deazapurins useful as inhibitors of januskinases | |
EP2090577A8 (en) | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2007089335A3 (en) | Multicyclic amino acid derivatives and methods of their use | |
WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
WO2006028963A3 (en) | Substituted heterocyclic compounds and uses thereof | |
WO2010093727A8 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2007115620A3 (en) | Novel cyclobutyl compounds as kinase inhibitors | |
MX2011006006A (en) | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. | |
WO2008054698A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
MX2009010127A (en) | N-heterocyclic compounds useful as inhibitors of janus kinases. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2636077 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008071135 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501616 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569706 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 192751 Country of ref document: IL Ref document number: 2007207743 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/009048 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007718125 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551297 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3974/CHENP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007207743 Country of ref document: AU Date of ref document: 20070111 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087019941 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2008-010211 Country of ref document: CR Ref document number: 200801716 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780009708.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0706621 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080718 |